News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Calibrant Announces Brain Cancer Drug Discovery Program with Cleveland Clinic


Posted on: 01/26/2008

Calibrant Announces Brain Cancer Drug Discovery Program with Cleveland Clinic

GAITHERSBURG, Md.--(BUSINESS WIRE)--Calibrant Biosystems today announced a research collaboration with the Cleveland Clinic to identify novel drug targets for primary brain cancer using Calibrants Gemini proteomics platform. As part of the partnership, Calibrant will identify protein networks and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma multiforme (GBM).

Our collaboration represents another important cancer drug program for Calibrant, stated Dr. Brian Balgley, Chief Technology Officer of Calibrant Biosystems. The study reflects Calibrants ability to apply the Gemini platform to targeted discovery from microdissected cell populations for the effective identification of disease-relevant pathways and drug targets. Calibrants collaborator, Robert J. Weil, M.D., is the Melvin Burkhardt Chair of Brain Tumor Research and Director of Laboratory Research in the Brain Tumor & Neuro-Oncology Center at Cleveland Clinic.

This latest partnership with the Cleveland Clinic adds tremendous value to Calibrants existing drug discovery collaborations. Calibrant has recently established several drug discovery collaborations with world-renowned medical research centers this year, leading to active therapeutic programs for cancer indications including breast and ovarian cancer.

About Calibrant Biosystems

Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrants advanced Gemini discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the unique ability to comparatively map protein networks between different cell types within a single tissue section. With an initial focus on monoclonal antibody drug development in oncology, Calibrant is leveraging the Gemini platform for the development of first-in-class therapeutics across a range of cancer indications. More information is available at www.calibrant.com.

Note: Gemini is a trademark of Calibrant Biosystems.

 

Contacts

Calibrant Biosystems
Dr. Michael Salgaller
Chief Operating Officer
301-977-7900
michael.salgaller@calibrant.com


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740